NCCM
CORT icon

Nine Chapters Capital Management’s Corcept Therapeutics CORT Stock Holding History

Nine Chapters Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-14,000
Closed -$61K – 959
2014
Q1 		$61K Buy
+14,000
New +$48.9K 0.01% 778

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Nine Chapters Capital Management's CORT Position: Q2 2014 in Review

Nine Chapters Capital Management sold out of Corcept Therapeutics (CORT) in Q2 2014, closing a stake of 14,000 shares — an estimated $61K sold.

Nine Chapters Capital Management first reported a position in CORT in Q1 2014 and held it in 1 quarter. The position peaked at $61K in Q1 2014. 62 funds tracked by Wall St. Rank hold CORT as of Q2 2014.

  • Nine Chapters Capital Management reported no remaining Corcept Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Nine Chapters Capital Management sold 14,000 Corcept Therapeutics shares in Q2 2014, an estimated $61K.
  • Nine Chapters Capital Management first reported a position in Corcept Therapeutics in Q1 2014 and held it in 1 quarter.
  • Nine Chapters Capital Management's Corcept Therapeutics position peaked at $61K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2014.

Based on Nine Chapters Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.